Shin Nippon Biomedical Laboratories, Ltd. YB3.F Stock
Shin Nippon Biomedical Laboratories, Ltd. Price Chart
Shin Nippon Biomedical Laboratories, Ltd. YB3.F Financial and Trading Overview
Contents
- Shin Nippon Biomedical Laboratories, Ltd. Price Chart
- Shin Nippon Biomedical Laboratories, Ltd. YB3.F Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Shin Nippon Biomedical Laboratories, Ltd.
- Q&A For Shin Nippon Biomedical Laboratories, Ltd. Stock
Shin Nippon Biomedical Laboratories, Ltd. stock price | 8.85 EUR |
Previous Close | 13.7 EUR |
Open | 14.1 EUR |
Bid | 14.1 EUR x 43300 |
Ask | 14.9 EUR x 40900 |
Day's Range | 14.1 - 14.1 EUR |
52 Week Range | 13.3 - 21.6 EUR |
Volume | 14 EUR |
Avg. Volume | 0 EUR |
Market Cap | 602.18M EUR |
Beta (5Y Monthly) | 0.157088 |
PE Ratio (TTM) | 14.536082 |
EPS (TTM) | 0.8 EUR |
Forward Dividend & Yield | 0.33 (2.33%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | N/A |
YB3.F Valuation Measures
Enterprise Value | 8.96B EUR |
Trailing P/E | 14.536082 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.023999933 |
Price/Book (mrq) | 0.02239485 |
Enterprise Value/Revenue | 0.357 |
Enterprise Value/EBITDA | 1.309 |
Trading Information
Shin Nippon Biomedical Laboratories, Ltd. Stock Price History
Beta (5Y Monthly) | 0.157088 |
52-Week Change | 0.71% |
S&P500 52-Week Change | 20.43% |
52 Week High | 21.6 EUR |
52 Week Low | 13.3 EUR |
50-Day Moving Average | 16.24 EUR |
200-Day Moving Average | 17.2 EUR |
YB3.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 41.63M |
Float | 20.19M |
Short Ratio | N/A |
% Held by Insiders | 52.38% |
% Held by Institutions | 20.10% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 50 |
Trailing Annual Dividend Yield | 364.96% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.3341 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 24.15% |
Operating Margin (ttm) | 20.90% |
Gross Margin | 48.52% |
EBITDA Margin | 27.28% |
Management Effectiveness
Return on Assets (ttm) | 6.79% |
Return on Equity (ttm) | 26.26% |
Income Statement
Revenue (ttm) | 25.09B EUR |
Revenue Per Share (ttm) | 602.68 EUR |
Quarterly Revenue Growth (yoy) | 81.59% |
Gross Profit (ttm) | 13.05B EUR |
EBITDA | 6.85B EUR |
Net Income Avi to Common (ttm) | 6.06B EUR |
Diluted EPS (ttm) | 0.97 |
Quarterly Earnings Growth (yoy) | -9.099% |
Balance Sheet
Total Cash (mrq) | 10.53B EUR |
Total Cash Per Share (mrq) | 253.01 EUR |
Total Debt (mrq) | 18.76B EUR |
Total Debt/Equity (mrq) | 71.17 EUR |
Current Ratio (mrq) | 1.137 |
Book Value Per Share (mrq) | 629.609 |
Cash Flow Statement
Operating Cash Flow (ttm) | 4B EUR |
Levered Free Cash Flow (ttm) | -2726853376 EUR |
Profile of Shin Nippon Biomedical Laboratories, Ltd.
Country | Germany |
State | N/A |
City | Tokyo |
Address | St. Luke’s Tower |
ZIP | 104-0044 |
Phone | 81 3 5565 5001 |
Website | https://www.snbl.co.jp |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 1208 |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
Q&A For Shin Nippon Biomedical Laboratories, Ltd. Stock
What is a current YB3.F stock price?
Shin Nippon Biomedical Laboratories, Ltd. YB3.F stock price today per share is 8.85 EUR.
How to purchase Shin Nippon Biomedical Laboratories, Ltd. stock?
You can buy YB3.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shin Nippon Biomedical Laboratories, Ltd.?
The stock symbol or ticker of Shin Nippon Biomedical Laboratories, Ltd. is YB3.F.
Which industry does the Shin Nippon Biomedical Laboratories, Ltd. company belong to?
The Shin Nippon Biomedical Laboratories, Ltd. industry is Diagnostics & Research.
How many shares does Shin Nippon Biomedical Laboratories, Ltd. have in circulation?
The max supply of Shin Nippon Biomedical Laboratories, Ltd. shares is 42.68M.
What is Shin Nippon Biomedical Laboratories, Ltd. Price to Earnings Ratio (PE Ratio)?
Shin Nippon Biomedical Laboratories, Ltd. PE Ratio is 11.06250000 now.
What was Shin Nippon Biomedical Laboratories, Ltd. earnings per share over the trailing 12 months (TTM)?
Shin Nippon Biomedical Laboratories, Ltd. EPS is 0.8 EUR over the trailing 12 months.
Which sector does the Shin Nippon Biomedical Laboratories, Ltd. company belong to?
The Shin Nippon Biomedical Laboratories, Ltd. sector is Healthcare.